Bangers In MASH: How Rezdiffra's Rivals Stack Up
A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.
A Visual Trip Through The Psychedelic Pipeline
An infographic looking at the status and origins of 39 psychedelic drug development programs being pursued by 26 sponsors.
Weighty Matters: The Obesity Market Now… And In Years To Come
INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.
Downturn Hit UK Biotech In 2023 But New Pension Funds Could Fuel Growth
Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.
Biopharma’s Winners And Losers Of 2023: Obesity Drugs Reshape Big Pharma
Novo Nordisk and Eli Lilly kickstarted an obesity drug revolution in 2023, just as investors cooled on biopharma’s vaccine saviors as the world looked to move on from COVID-19.
Top 10 Best-Selling Drugs Of Q3 2023: Ozempic Challenges Humira As Keytruda Extends Leadership
As Merck & Co’s checkpoint inhibitor Keytruda further cemented its position at the top of the best-selling drugs list, biosimilar-challenged Humira sales fell once again. Meanwhile, Novo Nordisk’s diabetes injection Ozempic continued its ascent.
India CEO Pay: Up, Up For Most, Eye On Gender Pay Gap As Women Execs Rise
C-suite remuneration at leading listed foreign and domestic drug firms in India rose in double digits for the most part in 2022-23, data compiled by Scrip show. While MDs/CEOs at domestic firms continue to take home sizeably higher earnings, the arrival of women leaders at the helm in some foreign firms puts the spotlight on gender pay parity.
Corporate VCs Play A Bigger Role In Hard Times
The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.
Biotech IPOs Get Bigger, But Not Necessarily Better
The first $1bn quarter since 2021 suggests that biotech’s IPO window is opening once more. But times remain tough, and many recently listed groups have seen their valuations fall.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.
Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In
The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.
A Closer Look: Commercial Impact For Drugs Up For Medicare Price Negotiation
An infographic looking at commercial factors for the 10 drugs chosen for Medicare price negotiation in 2026 under the Inflation Reduction Act (IRA). The graphics below review the valuations of these drugs, both past and forecast, as well as their relative contributions to the top-lines of the companies that own them.
Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List
The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.
Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program
Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.
Industry's Suits Against Medicare Price Negotiation: Consolidation And Expansion
With a new suit from Boehringer Ingelheim and a consolidated schedule for other cases, the legal threats to the US Medicare drug price negotiation program mandated under the Inflation Reduction Act (IRA) become clearer. Our tracker keeps you apprised of the latest developments.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.